CD59 Monoclonal Antibody

說明書

中文名稱：

CD59鼠單克隆抗體
貨號：

CSB-MA0049471A0m
規(guī)格：

￥1320
圖片：
Immunohistochemical of paraffin-embedded Human breast cancer using CSB-MA0049471A0m (2E11-2B5) at dilution of 1:200.

Immunohistochemical of paraffin-embedded human placenta tissue using CSB-MA0049471A0m (2E11-2B5) at dilution of 1:200.

All lanes: Mouse Anti-CD59 monoclonal antibody at 1μg/ml
Lane 1:K562
Predicted band size : 15kd
Observed band size : 22kd
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

CD59單克隆抗體（CUSABIO貨號：CSB-MA0049471A0m）是靶向人類補體調(diào)節(jié)蛋白CD59的高特異性科研試劑，該靶標作為關(guān)鍵的膜結(jié)合調(diào)控因子，通過抑制膜攻擊復(fù)合物（MAC）的形成保護宿主細胞免受補體介導(dǎo)的溶解作用。本產(chǎn)品經(jīng)嚴格驗證適用于ELISA、Western Blot及免疫組化（IHC）三大實驗平臺，抗體效價穩(wěn)定且具有優(yōu)異的抗原結(jié)合特異性，可精準識別內(nèi)源性CD59蛋白表達。在腫瘤免疫微環(huán)境研究、補體系統(tǒng)調(diào)控機制探索、血液系統(tǒng)疾病模型構(gòu)建等科研領(lǐng)域具有重要應(yīng)用價值，特別適用于探究CD59在腫瘤免疫逃逸、再生障礙性貧血、陣發(fā)性睡眠性血紅蛋白尿等病理過程中的分子調(diào)控網(wǎng)絡(luò)。該抗體為凍干粉劑型，提供1mg規(guī)格包裝，經(jīng)SDS-PAGE驗證純度達95%以上，批間一致性經(jīng)多克隆位點驗證保障，是研究補體信號通路及其相關(guān)疾病機制的理想工具。
產(chǎn)品名稱：

mouse anti-Homo sapiens (Human) CD59 monoclonal antibody
Uniprot No.：

P13987
基因名：

CD59
別名：

16.3A5 antibody; 1F5 antibody; 1F5 antigen antibody; 20 kDa homologous restriction factor antibody; CD 59 antibody; CD_antigen=CD59 antibody; CD59 antibody; CD59 antigen antibody; CD59 antigen complement regulatory protein antibody; CD59 antigen p18 20 antibody; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5; EJ16; EJ30; EL32 and G344) antibody; CD59 glycoprotein antibody; CD59 molecule antibody; CD59 molecule complement regulatory protein antibody; CD59_HUMAN antibody; Cd59a antibody; Complement regulatory protein antibody; EJ16 antibody; EJ30 antibody; EL32 antibody; FLJ38134 antibody; FLJ92039 antibody; G344 antibody; HRF 20 antibody; HRF-20 antibody; HRF20 antibody; Human leukocyte antigen MIC11 antibody; Ly 6 like protein antibody; Lymphocytic antigen CD59/MEM43 antibody; MAC inhibitory protein antibody; MAC IP antibody; MAC-inhibitory protein antibody; MAC-IP antibody; MACIF antibody; MACIP antibody; MEM43 antibody; MEM43 antigen antibody; Membrane attack complex (MAC) inhibition factor antibody; Membrane attack complex inhibition factor antibody; Membrane inhibitor of reactive lysis antibody; MGC2354 antibody; MIC11 antibody; MIN1 antibody; MIN2 antibody; MIN3 antibody; MIRL antibody; MSK21 antibody; p18 20 antibody; Protectin antibody; Surface antigen recognized by monoclonal antibody 16.3A5 antibody; T cell activating protein antibody
宿主：

mouse
反應(yīng)種屬：

Human
免疫原：

Recombinant CD59 Protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

monoclonal
抗體亞型：

IgG1
純化方式：

>95%,protein G purifed
克隆號：

2E11B6
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

liquid
應(yīng)用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:500

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.; The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.
基因功能參考文獻：
1. Parainfluenza Virus 5 (PIV5) containing CD59 antigens (PIV5-CD59) shows increased resistance to complement-mediated neutralization in vitro comparing to PIV5 lacking regulators. Infection of A549 cells with PIV5 upregulates CD59 expression. TGF-beta treatment of PIV5-infected cells also increases cell surface CD59 expression and progeny virions are more resistant to complement-mediated neutralization. PMID: 29693588
2. Nonfunctioning CD59 is a major risk factor for stroke and hypercoagulability. PMID: 29929138
3. Therapeutic strategies that seek to modulate the functions of CD59 in the tumor microenvironment could be a promising direction for tumor immunotherapy. PMID: 29521526
4. This study demonstrated that Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients. PMID: 29458425
5. Movement of Domain 2 with respect to Domain 3 of ILY is essential for forming a late prepore intermediate that releases CD59, while the role of cholesterol may be limited to insertion of the transmembrane segments. Together these data define a structural timeline for ILY pore formation and suggest a mechanism that is relevant to understanding other pore-forming toxins that also require CD59. PMID: 27910935
6. CD59 polymorphisms are associated with gene expression and different sexual susceptibility to pemphigus foliaceus in the Brazilian patients. PMID: 28534443
7. we demonstrated that CD59 regulation by SOX2 is required for stem cell evasion of complement surveillance. This finding highlights the importance of complement surveillance in eliminating CSCs and may suggest CD59 as a potential target for cancer therapy. PMID: 28017655
8. The results indicate that shear stress is an important mediator in endothelial progenitor cells expression of CD59 regulated by the extacellular matrix-integrin alphaVbeta3-F-actin pathway, which is a key factor in preventing membrane attack complex-mediated cell autolysis. PMID: 28943429
9. Data show that following 4 patients with CD59 Cys89Tyr mutations who are treated with eculizumab, no strokes occurred and non-permanent neurological insults underwent resolution without any new neurological exacerbations. PMID: 28622911
10. our results indicate that the Lys(41) /His(44) glycation motif in human CD59 may confer humans a higher risk of developing vascular disease in response to hyperglycemia. PMID: 28815695
11. Structural basis for receptor recognition by the human CD59-responsive cholesterol-dependent cytolysins has been presented. PMID: 27499440
12. developed a model of conditional and targeted cell ablation by generating floxed STOP-CD59 knockin mice (ihCD59), in which expression of human CD59 only occurs after Cre-mediated recombination PMID: 27159394
13. Our results revealed that SNPs CD59-rs831626 and CFH-rs1065489 were associated with the susceptibility of acute anterior uveitis. PMID: 27419833
14. Novel disorder caused by CD59 deficiency or nonfunctional CD59 at the cell membrane presenting with symptoms characteristic of classical GBS or CIDP. PMID: 27568864
15. Single-fluorescent-molecule imaging in the live-cell plasma membrane revealed the clear but transient colocalization and codiffusion of fluorescent ganglioside analogs with a fluorescently labeled glycosylphosphatidylinisotol (GPI)-anchored protein, human CD59, with lifetimes of 12 ms for CD59 monomers, 40 ms for CD59's transient homodimer rafts in quiescent cells. PMID: 27043189
16. There is an altered pattern of CD55 and CD59 expression on RBCs of SCD Patients; however, it does not seem to play a causal role in the pathophysiology of anemia, and is unlikely to be influenced by the level of erythropoietin or other inflammatory mediators. PMID: 27667587
17. Study revealed that CD59 is overexpressed in breast cancer tumors and correlates with poor survival. PMID: 26935178
18. A Promoter Polymorphism in the CD59 Gene in Donor Lungs Correlates With a Higher Risk for Chronic Rejection After Lung Transplantation. PMID: 26517734
19. Urinary CD59 and alpha-1 antitrypsin are significantly altered in hypertensive patients developing albuminuria. PMID: 26772976
20. levels of CSF CD59 in neuromyelitis optica and multiple sclerosis PMID: 26686775
21. Increased internalization of endothelial CD59 in intermittent hypoxia appeared to be cholesterol-dependent and was reversed by statins in a CD59-dependent manner. PMID: 26738794
22. Low urine CD59 expression is associated with clear cell renal cell carcinoma. PMID: 26420021
23. Decreased CD59 expression in threatened miscarriage at late gestational ages leads to additional activation of a maternal immune response and serves as a possible predictor for premature birth. PMID: 26978230
24. Data show that the palmitoylation mutation of linker for activation of T cells (LAT)attenuated the signal transduction induced by glycosylphosphatidylinositol-anchored CD59 antigen in T cells. PMID: 26271970
25. After blockage of CD59 function, the reactive Abs, regardless of their neutralizing activities, significantly enhanced specific ADCML of HIV-1 virions PMID: 26136568
26. Genetic risk at the CFH-to-F13B locus was associated with higher levels of complement activation at the human macular RPE-choroid interface, as was cigarette smoking. Levels of CRP were substantially elevated in risk donors with smoking history. PMID: 26218915
27. A primary homozygous Cys89Tyr CD59 deficiency in humans resulted in the amino acid substitution p.Cys89Tyr with ensuing failure of proper localization of the CD59 protein to the cell surface. (Review) PMID: 25818314
28. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP antineoplastic protocol. PMID: 24924474
29. Data suggest that microRNA-224 directly down-regulates CD59 antigen expression in diffuse large B-cell lymphoma by binding to CD59 3'-untranslated region. PMID: 25146331
30. Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. PMID: 25725314
31. The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. PMID: 24463881
32. Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells. PMID: 25149467
33. Data indicate that down-regulation of CD59 expression could inhibit HeLa cells' proliferation and promote apoptosis, and the inhibitory effect of peptide seal was better than that of CD59 interference plasmid. PMID: 24909278
34. The expression levels of CD46, CD55, and CD59 were significantly higher in colon cancer tissues compared with the normal adjacent colon tissues. PMID: 24978917
35. this study observed robust relationships between a single measurement of blood levels of GCD59 and both acute (2-hour OGTT) and chronic (HbA1c) measures of glucose handling. PMID: 24628556
36. Hemolytic uremic syndrome evolved independently from CD55 and CD59 expression on peripheral blood cells in enteroaggregative E.coli O104:H4 infected patients. PMID: 24086391
37. Data suggest that CD59 gene might be a genetic locus for the therapy of atherosclerosis. PMID: 24084445
38. We found that CD46 and CD59 were decreased in retinal pigment epithelium cells in part, by their release in exosomes and apoptotic particles. PMID: 24664706
39. Use of AAV2/8-sCD59 warrants further exploration as a potential therapy for advanced stages of diabetic retinopathy PMID: 24167638
40. Sp1 may regulate the expression of CD59, whereas CREB-binding protein (CBP)/p300 bridge NF-kappaB and CREB, which functions as an enhancer-binding protein to induce the up-regulation of CD59 during in lipopolysaccharide (LPS)-triggered complement activation. PMID: 24338025
41. CD59 silencing in NSCLC cancer cells via retrovirus-mediated RNAi can enhance complement-mediated cell apoptosis, inhibiting the growth of NSCLC. CD59 may serve as a potential target for gene therapy in NSCLC PMID: 23835643
42. mutation of palmitoylation site of LAT-EGFP attenuated the signal transduction of CD59 in T cells PMID: 24200054
43. The primary CD59-ILY binding site is composed of a side-to-side contact between the beta hairpin extension of ILY D4 and the core beta sheet of CD59. PMID: 23665225
44. Data show that increased CD35, CD46, CD55 and CD59 on neutrophils and monocytes present potent markers of bacterial infection and viral infection. PMID: 23376460
45. Hematology and diabetes: from hemoglobin A1c to CD59 glycation. PMID: 23757192
46. a novel, sensitive, and specific ELISA for measuring GCD59 in blood. The assay distinguished individuals with diabetes from those without, and showed strong correlation between GCD59 and HbA1c. PMID: 23670858
47. CD59 was a type of membrane-bound protein, CD59 and Cbp played synergistic roles in cell activation and proliferation. PMID: 23746236
48. HCV incorporates selectively CD59, but not CD46 or CD55, in its envelope to gain resistance to CML in serum of infected individuals PMID: 23049856
49. A Cys89Tyr mutation is associated with improper cell-surface localization of CD59. This mutation is manifested clinically in infancy by chronic hemolysis & relapsing peripheral demyelinating disease. PMID: 23149847
50. findings demonstrated that decreased CD59 expression on T cells significantly enhanced activation and proliferation of CD4( ) T cells and CD8( ) T cells; data support that CD59 down-regulates antigen-specific activation of T lymphocytes in a ligand-dependent manner PMID: 22480874
顯示更多

收起更多
相關(guān)疾病：

Hemolytic anemia, CD59-mediated, with or without polyneuropathy (HACD59)
亞細胞定位：

Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Soluble form found in a number of tissues.
數(shù)據(jù)庫鏈接：

HGNC: 1689

OMIM: 107271

KEGG: hsa:966

STRING: 9606.ENSP00000340210

UniGene: Hs.278573

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human